This resistance is likely driven by the tumor's molecular profile, which frequently includes mutations in TP53, ARID1A, PIK3CA, and PTEN pathways, making EC difficult to treat and emphasizing the need for better therapies. The gene discussed is TP53; the disease is neoplasm.